anastrozole has been researched along with Adverse Drug Event in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Shapiro, AC | 1 |
| Adlis, SA | 1 |
| Robien, K | 1 |
| Kirstein, MN | 1 |
| Liang, S | 1 |
| Richter, SA | 1 |
| Lerner, RE | 1 |
| Carpenter, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Study Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors[NCT01509079] | Phase 2 | 116 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
adherence measured with pill counts for the vitamin D at predesignated study timepoints: baseline (after run-in), 3 months and 6 months (NCT01509079)
Timeframe: average for all study ppts for: screening to baseline; baseline to 3 months; 3 month to 6 months
| Intervention | % of adherence for each treatment arm (Number) |
|---|---|
| Vitamin D3 4000 IU | 95 |
| Vitamin D3 600 IU | 95 |
(NCT01509079)
Timeframe: baseline to 6 months
| Intervention | pounds (Mean) |
|---|---|
| Vitamin D3 4000 IU | 1.8 |
| Vitamin D3 600 IU | 1.0 |
The MS subscale is a self-reported measure on a scale of 0 to 4, with lower score indicating less arthralgia/myalgia (NCT01509079)
Timeframe: baseline to 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Vitamin D3 4000 IU | -0.2 |
| Vitamin D3 600 IU | -0.5 |
PROMIS measures physical functioning on the short form and higher scores reflect better physical functioning with 10 questions on daily activities of life on a Likert scale ranging from 5 (no problem performing activity) to 1 (cannot do activity). Range on this measure is from 50 (best)-10 (worst). (NCT01509079)
Timeframe: baseline to 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Vitamin D3 4000 IU | 0.6 |
| Vitamin D3 600 IU | 1.7 |
GLM Mean and standard deviation of Whole Body Bone Mineral Density (grams/cm2) of Trial Participants by Treatment Arm after controlling for bisphosphonate use (NCT01509079)
Timeframe: From Baseline and 6 months of D3 supplementation
| Intervention | gm/cm2 (Geometric Least Squares Mean) |
|---|---|
| Vitamin D3 4000 IU | 1.1 |
| Vitamin D3 600 IU | 1.12 |
Difference in steady state concentrations in plasma from baseline to 6 months (NCT01509079)
Timeframe: baseline to 6 months
| Intervention | mg/L (Mean) | |
|---|---|---|
| anastrozole | letrozole | |
| Vitamin D3 4000 IU | -1.31 | 2.16 |
| Vitamin D3 600 IU | 2.4 | -0.83 |
(NCT01509079)
Timeframe: baseline and 6 months
| Intervention | pg/ml (Geometric Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Vitamin D3 4000 IU | 2.83 | 2.94 |
| Vitamin D3 600 IU | 2.77 | 3.0 |
1 review available for anastrozole and Adverse Drug Event
| Article | Year |
|---|---|
Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2008 |
1 trial available for anastrozole and Adverse Drug Event
| Article | Year |
|---|---|
Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Bone De | 2016 |
3 other studies available for anastrozole and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |